CV Therapeutics, which markets Ranexa (ranolazine), has rejected a buyout bid from Astellas Pharma.
One-stop source for cardiology news and links
CV Therapeutics, which markets Ranexa (ranolazine), has rejected a buyout bid from Astellas Pharma.
Click here to read the Astellas press release.
Click here to read the response from CV Therapeutics.
Developed By: SKSDEV
"I’d rather read Larry Husten on clinical trials than the constipated editorials in peer review journals." --Saurabh Jha (The Health Care Blog)
Copyright © 2026 · Prose on Genesis Framework · WordPress · Log in
[…] CV Therapeutics, the company that manufactures ranolazine (Ranexa) and regadenoson (Lexiscan). As we reported back in January, CV Therapeutics previously rejected a friendly bid at the same price from Astellas. Astellas […]